查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1284233

2028 年癌症疫苗市場預測——按產品類型、技術、應用、最終用戶和地區進行的全球分析

Cancer Vaccines Market Forecasts to 2028 - Global Analysis By Product Type, Technology, Application, End users and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC，2022年全球癌症疫苗市場規模將達到75億美元，預測期內以16.7%的複合年增長率增長，2028年將達到189.5億美元，預計將達到美元。

癌症疫苗是被視為生物反應調節劑的藥物。 這種生物反應調節劑通過提高人體免疫系統抗癌能力發揮作用。 有兩種類型的癌症疫苗：治療性和預防性。 預防性癌症疫苗用於預防健康人的癌症。 另一方面，癌症患者接受治療性癌症疫苗以增強免疫力來對抗癌症。 從兒童到成人，癌症疫苗都可以通過靜脈滴注進行接種。

據世界癌症研究基金會（WCRF）統計，2020年全球約有1810萬癌症患者，其中男性930萬，女性880萬。

市場動態：

驅動程序

擴大主要市場參與者之間的戰略合作夥伴關係

這個市場的特點是默克公司和葛蘭素史克公司等行業參與者非常關注新型疫苗的推出。 然而，缺乏產品批准和新疫苗管道中治療適應症的不平衡引發了人們對巨大市場缺口的擔憂。 此外，致力於開發新型癌症疫苗的中小型生物技術公司和學術機構正在努力獲得資金和投資。 因此，正在採用鼓勵合作的新商業模式來進入國際市場，並將尖端的新產品推向市場。 因此，許多從事預防和治療疫苗研發的中型免疫治療公司現在都與業內知名公司合作，進行臨床試驗以評估疫苗的安全性和有效性。

約束

因個性化醫療的進步而限制使用癌症疫苗

癌症是世界上主要的死亡原因之一，是一種複雜且異質性強的疾病。 治療性癌症疫苗針對的是癌細胞而不是疾病的根本原因，而預防性癌症疫苗則致力於增強人體對疾病的自然防禦能力。 此外，這些疫苗是一種免疫療法，只有少數癌症類□□型獲得了全球產品批准。 一些癌症類型（結直腸癌、乳腺癌、非霍奇金淋巴瘤）根據分子亞型進一步細分。 此外，根據癌症的部位和階段，即使在同一腫瘤內，特定標誌物的表達方式也不同。 除了癌症疫苗，還需要更精確的治療來改善這些癌症的預後。 一種新的腫瘤預防和治療方法是個性化或精準醫療。 有可能針對腫瘤中的促癌因子並以影響其環境的方式改變治療。

機會

擴大癌症疫苗的臨床試驗

PDAC（胰腺導管腺癌）是一種常見的胰腺癌，目前尚無治愈方法。 BioNTech 開發的 PDAC 疫苗的 1 期臨床試驗數據已經發布。 由 BioNTech 開發的 mRNA 疫苗用於將新抗原遺傳密碼傳遞給患者的細胞。 該代碼告訴細胞產生新抗原，即癌細胞產生的蛋白質。 這些蛋白質用於幫助免疫系統直接攻擊腫瘤。

威脅

監管審批時間長，開發成本高

由於開發癌症疫苗的成本高且製造疫苗所需的時間長，預計在預測期內市場發展將受到限制。 此外，在即將推出的疫苗管線中，缺乏產品批准和治療適應症的不平衡威脅著市場的巨大缺口。

COVID-19 的影響：

2020 年 1 月 30 日，世界衛生組織 (WHO) 宣布 COVID-19 疫情為全球關注的突發公共衛生事件。 全球共有 210 個國家/地區受到 COVID-19 的影響。 隨著幾個受 COVID-19 影響的國家關閉，以及在 COVID-19 大流行之後生病的醫護人員增加，導致短缺，製造和銷售癌症疫苗的公司被迫將影響降至最低

Clairvacs 細分市場預計將成為預測期內最大的細分市場

CreaVax 預計將在預測期內顯著擴張。 一種基於自體樹突狀細胞的癌症疫苗，使用患者的外周血單核細胞 (PBMC) 在用腫瘤裂解物和 KLH 致敏後成熟為樹突狀細胞（匙孔血藍蛋白）。 Creagene 推出了 Creavax，一種治療腎細胞癌的疫苗。 CreaVax 對肝細胞癌的療效目前正在 III 期臨床試驗中進行研究。

預計成人疫苗部分在預測期內的複合年增長率最高

成人疫苗細分市場佔據了最大的市場份額。 此外，世界各地的許多研究人員正在進行深入研究，以開發有效的候選疫苗，以實現潛在的治療策略。 例如，2022 年 3 月，馬裡蘭州的 Northwest Biotherapeutics 將在其位於英國索斯頓的新製造工廠推出第一種具有先進療法的個性化樹突狀細胞藥物，用於治療膠質母細胞瘤病例。我們將宣布，我們將開始出於同情的原因生產癌症疫苗。

市場份額最高的地區

北美的收入份額最高。 在預測期內推動市場的因素包括癌症發病率上升、研究支出增加、市場進入者增加臨床試驗以及癌症疫苗的監管批准。 例如，美國癌症協會預測，2021 年美國將有 608,570 例癌症死亡和 190 萬例新癌症病例。 與此同時，預計到 2022 年將有近 190 萬美國人被診斷出患有癌症。 乳腺癌將成為 2018 年最常見的癌症診斷，估計影響 287,850 名女性和 2,710 名男性。 前列腺癌是男性最常見的癌症診斷，也是第二大最常見的癌症診斷。

複合年增長率最高的地區：

歐洲市場預計將顯著增長。 這是由癌症疫苗需求增加、癌症患病率上升、歐洲癌症協會和該地區新興市場參與者對研究的支持增加等因素推動的。這被認為是由於其對疫苗市場的積極影響.

主要發展：

2022 年 6 月，生物技術公司 Treos Bio Limited 宣布了 Polypepi 1018 與 F. Hoffmann-La Roche AG 的 pd-l1 抑製劑聯合用於治療轉移性結直腸癌的第 2 期臨床試驗。宣布試驗中的第一位患者已經服藥了。

2020年10月，處於臨床階段的生物製藥公司Vaccibody AS與羅氏集團成員Genentech合作，開髮用於治療癌症的基於DNA的個性化新抗原疫苗（DNA癌症疫苗）。宣布它已經簽訂了一項全球許可和合作協議，用於開發和商業化

2020 年 6 月，UbiVac, Inc. 和 Bristol-Myers Squibb 公佈了 UbiVac 的在研產品 DPV-001 聯合免疫療法治療晚期三陰性乳腺癌的安全性、耐受性和初步結果。宣佈建立臨床試驗合作夥伴關係以評估它的功效。

這份報告提供了什麼

  • 區域和國家級細分市場的市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場趨勢（驅動因素、制約因素、機會、威脅、挑戰、投資機會、建議）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射關鍵共同趨勢。
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制優惠：

購買此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶的要求對主要國家/地區的市場估計/預測/複合年增長率（注意：基於可行性檢查）。
  • 競爭基準
    • 根據產品組合、區域影響力和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二級研究來源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球癌症疫苗市場：按產品類型分類

  • 癌症預防疫苗
  • 治療性癌症疫苗

第 6 章全球癌症疫苗市場：按技術分類

  • 樹突狀細胞 (DC) 癌症疫苗
  • 重組癌症疫苗
  • 全細胞癌疫苗
  • 抗原/輔助癌症疫苗
  • 病毒載體和 DNA 癌症疫苗
  • 亞單位疫苗
  • 結合疫苗
  • 滅活□□疫苗
  • 減毒活疫苗
  • 其他技術

第 7 章全球癌症疫苗市場：按應用

  • 前列腺癌
  • 宮頸癌
  • 其他用途

第 8 章全球癌症疫苗市場：按最終用戶分類

  • 兒科
  • 成人
  • 其他最終用戶

第 9 章全球癌症疫苗市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第10章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Aduro Biotech Inc.
  • Advaxis Inc.
  • Amgen Inc.
  • Argos Therapeutics
  • Astellas Pharma Inc.
  • Astrazeneca Plc.
  • Batavia Bioservices,
  • Bristol-Myers Squibb Company
  • Csl Limited
  • Dandrit Biotech
  • Dynavax Technologies Corporation
  • Generex Biotechnology Corporation
  • Immunocellular Therapeutics, Ltd
  • Merck & Co., Inc.
  • Sanpower Corporation
  • Sanpower Group Co. Ltd.
  • Vaccinogen, Inc.
Product Code: SMRC23065

According to Stratistics MRC, the Global Cancer Vaccines Market is accounted for $7.50 billion in 2022 and is expected to reach $18.95 billion by 2028 growing at a CAGR of 16.7% during the forecast period. Cancer vaccines are drugs that are thought of as biological response modifiers. These biological response modifiers work by boosting the body's immune system's capacity to combat cancer. There are two different kinds of cancer vaccines: therapeutic and preventative. In order to prevent cancer in healthy individuals, preventive cancer vaccines are used. In order to boost their immune systems ability to combat the disease, cancer patients receive therapeutic cancer vaccines. Children and adults alike can receive cancer vaccines intravenously .

According to statistics published by the World Cancer Research Fund (WCRF), there were about 18.1 million cancer cases worldwide in 2020, of which 9.3 million were males and 8.8 million females.

Market Dynamics:

Driver:

Growing strategic partnerships among major market players

The market is characterized by a significant focus on the introduction of novel vaccines by industry players like Merck & Co., Inc., GSK plc, and others. However, a sizable market gap is feared due to a lack of product approvals and an imbalance of therapeutic indications in the pipeline for new vaccines. Additionally, small and mid-size biotech businesses as well as academic institutions working to develop novel cancer vaccines are having trouble finding funding and investments. Therefore, new business models that encourage collaboration are being adopted so that these players can access international markets and provide the market with cutting-edge new products. As a result, a number of mid-sized immunotherapy players involved in the research and development of prophylactic and therapeutic vaccines are now working with well-known companies in the industry to carry out clinical trials to gauge the safety and effectiveness of vaccines.

Restraint:

Limiting the use of cancer vaccines with personalized medicine advances

Cancer, one of the leading causes of death worldwide, is a complex and heterogeneous disease. Therapeutic cancer vaccines target the cancer cells rather than the disease's underlying cause, whereas preventive cancer vaccines work to bolster the body's natural defenses against the disease. Additionally, these vaccines are a form of immunotherapy that only has a small number of cancer types for which they have received global product approval. Based on their molecular subtypes, some cancer types (colon, breast, and non-Hodgkin's lymphoma) have even more detailed classifications. Additionally, the location or stage of the cancer affects how certain markers are expressed within the same tumor. In order to improve the prognosis for these cancer types, more precise treatment methods are required in addition to cancer vaccines. A new approach to prevention and treatment in oncology is personalized or precision medicine. It may alter treatment in ways that target the tumor's oncogenic drivers and influence its environment.

Opportunity:

The expansion of cancer vaccine clinical trials

PDAC, or pancreatic ductal adenocarcinoma, is a common form of pancreatic cancer for which there are no curative therapies. Data from the first phase of a clinical trial for BioNTech's PDAC vaccine against PDAC was made public. The mRNA vaccination developed by BioNTech is used to deliver the genetic code for the neoantigen to the patient's cells. The code instructs the cells to produce the neoantigens, proteins created by cancer cells. These proteins are produced to help the immune system attack the tumor directly.

Threat:

Lengthy regulatory approvals and high developing cost

Market growth is anticipated to be constrained during the forecast period due to the high cost of developing cancer vaccines and the prolonged time required for vaccine manufacturing. Additionally, a sizable market gap is threatened by a lack of product approvals and an imbalance of therapeutic indications in the pipeline of upcoming vaccines.

COVID-19 Impact:

On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of global concern. A total of 210 countries around the world have been impacted by COVID-19. Due to closures in several COVID-19-affected countries and an increase in the number of sick healthcare workers following the COVID-19 pandemic, which resulted in a shortage, companies that manufacture and distribute cancer vaccines have only been minimally impacted by COVID-19.

The creavax segment is expected to be the largest during the forecast period

CreaVax is expected to expand significantly during the forecast period. The patient's peripheral blood mononuclear cells (PBMC) are used to make the autologous dendritic cell-based cancer vaccine, which is sensitized with tumor lysate and KLH before maturing into dendritic cells (Keyhole Limpet Hemocyanin). Creagene released Creavax, a therapeutic vaccine for renal cell carcinoma. The effectiveness of CreaVax in the treatment of hepatocellular carcinoma is currently being studied in a Phase III clinical trial.

The adult vaccines segment is expected to have the highest CAGR during the forecast period

The adult vaccine market segment had the largest market share. Additionally, a large number of researchers around the world are conducting in-depth research to develop efficient vaccine candidates to realize potential therapeutic strategies. For instance, Northwest Biotherapeutics of Maryland will announce in March 2022 the start of production of the first personalized dendritic cell-based cancer vaccine at its new production facility in Sawston, UK, using advanced therapy medicinal products for the treatment of a glioblastoma case on compassionate grounds.

Region with highest share:

The largest revenue share came from North America. The factors driving the market during the forecast period include the rising incidence of cancer, rising research expenditures, an increase in clinical trials by industry participants, and regulatory approvals for cancer vaccines. For instance, the American Cancer Society predicts that in 2021 there will be 608,570 cancer deaths in the United States and an estimated 1.9 million new cancer cases. In contrast, the number of Americans who will receive a cancer diagnosis in 2022 will be close to 1.9 million. Breast cancer will be the most common cancer diagnosis in 2018, affecting an estimated 287,850 women and 2,710 men. The most frequent cancer diagnosis in men and the second most frequent overall is prostate cancer.

Region with highest CAGR:

Europe's market is expected to grow significantly. This can be attributed to factors such as the rising demand for cancer vaccines, the rising incidence of cancer, the increase in support for research studies from cancer societies across Europe, and emerging market players in the area, all of which have a positive impact on the market for dendritic cell cancer vaccines.

Key players in the market:

Some of the key players in Cancer Vaccines market include Aduro Biotech Inc., Advaxis Inc., Amgen Inc., Argos Therapeutics, Astellas Pharma Inc., Astrazeneca Plc., Batavia Bioservices, Bristol-Myers Squibb Company, Csl Limited, Dandrit Biotech, Dynavax Technologies Corporation, Generex Biotechnology Corporation, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Sanpower Corporation, Sanpower Group Co. Ltd. And Vaccinogen, Inc.

Key Developments:

In June 2022, Treos Bio Limited, a biotechnology company, announced the first patient dosed in a phase 2 trial of polypepi1018 in combination with pd-l1-inhibitor manufactured by F. Hoffmann-La Roche AG for the treatment of metastatic colorectal cancer.

In October 2020, Vaccibody AS, a clinical-stage biopharmaceutical company, announced its worldwide license and collaboration agreement with Genentech, Inc., a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines (DNA cancer vaccines) for the treatment of cancers.

In June 2020, UbiVac, Inc. announced a clinical trial collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of UbiVac's investigational product, DPV-001, in combination with Immunotherapy for Advanced Triple Negative Breast Cancer.

Product Types Covered:

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines

Technologies Covered:

  • Dendritic Cells (DC) Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Whole-cell Cancer Vaccines
  • Antigen/Adjuvant Cancer Vaccines
  • Viral Vector & DNA Cancer Vaccines
  • Subunit Vaccines
  • Conjugate Vaccines
  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Other Technologies

Applications Covered:

  • Prostate Cancer
  • Cervical Cancer
  • Other Applications

End Users Covered:

  • Pediatrics
  • Adults
  • Other End users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Vaccines Market, By Product Type

  • 5.1 Introduction
  • 5.2 Preventive Cancer Vaccines
  • 5.3 Therapeutic Cancer Vaccines

6 Global Cancer Vaccines Market, By Technology

  • 6.1 Introduction
  • 6.2 Dendritic Cells (DC) Cancer Vaccines
  • 6.3 Recombinant Cancer Vaccines
  • 6.4 Whole-cell Cancer Vaccines
  • 6.5 Antigen/Adjuvant Cancer Vaccines
  • 6.6 Viral Vector & DNA Cancer Vaccines
  • 6.7 Subunit Vaccines
  • 6.8 Conjugate Vaccines
  • 6.9 Inactivated Vaccines
  • 6.10 Live Attenuated Vaccines
  • 6.11 Other Technologies

7 Global Cancer Vaccines Market, By Application

  • 7.1 Introduction
  • 7.2 Prostate Cancer
  • 7.3 Cervical Cancer
  • 7.4 Other Applications

8 Global Cancer Vaccines Market, By End User

  • 8.1 Introduction
  • 8.2 Pediatrics
  • 8.3 Adults
  • 8.4 Other End Users

9 Global Cancer Vaccines Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Aduro Biotech Inc.
  • 11.2 Advaxis Inc.
  • 11.3 Amgen Inc.
  • 11.4 Argos Therapeutics
  • 11.5 Astellas Pharma Inc.
  • 11.6 Astrazeneca Plc.
  • 11.7 Batavia Bioservices,
  • 11.8 Bristol-Myers Squibb Company
  • 11.9 Csl Limited
  • 11.10 Dandrit Biotech
  • 11.11 Dynavax Technologies Corporation
  • 11.12 Generex Biotechnology Corporation
  • 11.13 Immunocellular Therapeutics, Ltd
  • 11.14 Merck & Co., Inc.
  • 11.15 Sanpower Corporation
  • 11.16 Sanpower Group Co. Ltd.
  • 11.17 Vaccinogen, Inc.

List of Tables

  • Table 1 Global Cancer Vaccines Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 3 Global Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
  • Table 4 Global Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
  • Table 5 Global Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
  • Table 6 Global Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
  • Table 7 Global Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
  • Table 8 Global Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
  • Table 9 Global Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
  • Table 10 Global Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
  • Table 11 Global Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
  • Table 12 Global Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
  • Table 13 Global Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
  • Table 14 Global Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
  • Table 15 Global Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
  • Table 16 Global Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
  • Table 17 Global Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
  • Table 18 Global Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
  • Table 19 Global Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 20 Global Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
  • Table 21 Global Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
  • Table 22 Global Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
  • Table 23 Global Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 24 North America Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
  • Table 25 North America Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 26 North America Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
  • Table 27 North America Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
  • Table 28 North America Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
  • Table 29 North America Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
  • Table 30 North America Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
  • Table 31 North America Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
  • Table 32 North America Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
  • Table 33 North America Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
  • Table 34 North America Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
  • Table 35 North America Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
  • Table 36 North America Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
  • Table 37 North America Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
  • Table 38 North America Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
  • Table 39 North America Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
  • Table 40 North America Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
  • Table 41 North America Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
  • Table 42 North America Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 43 North America Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
  • Table 44 North America Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
  • Table 45 North America Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
  • Table 46 North America Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 47 Europe Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
  • Table 48 Europe Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 49 Europe Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
  • Table 50 Europe Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
  • Table 51 Europe Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
  • Table 52 Europe Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
  • Table 53 Europe Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
  • Table 54 Europe Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
  • Table 55 Europe Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
  • Table 56 Europe Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
  • Table 57 Europe Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
  • Table 58 Europe Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
  • Table 59 Europe Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
  • Table 60 Europe Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
  • Table 61 Europe Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
  • Table 62 Europe Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
  • Table 63 Europe Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
  • Table 64 Europe Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
  • Table 65 Europe Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 66 Europe Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
  • Table 67 Europe Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
  • Table 68 Europe Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
  • Table 69 Europe Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 70 Asia Pacific Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
  • Table 71 Asia Pacific Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 72 Asia Pacific Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
  • Table 73 Asia Pacific Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
  • Table 74 Asia Pacific Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
  • Table 75 Asia Pacific Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
  • Table 76 Asia Pacific Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
  • Table 77 Asia Pacific Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
  • Table 78 Asia Pacific Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
  • Table 79 Asia Pacific Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
  • Table 80 Asia Pacific Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
  • Table 81 Asia Pacific Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
  • Table 82 Asia Pacific Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
  • Table 83 Asia Pacific Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
  • Table 84 Asia Pacific Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
  • Table 85 Asia Pacific Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
  • Table 86 Asia Pacific Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
  • Table 87 Asia Pacific Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
  • Table 88 Asia Pacific Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 89 Asia Pacific Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
  • Table 90 Asia Pacific Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
  • Table 91 Asia Pacific Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
  • Table 92 Asia Pacific Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 93 South America Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
  • Table 94 South America Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 95 South America Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
  • Table 96 South America Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
  • Table 97 South America Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
  • Table 98 South America Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
  • Table 99 South America Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
  • Table 100 South America Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
  • Table 101 South America Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
  • Table 102 South America Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
  • Table 103 South America Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
  • Table 104 South America Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
  • Table 105 South America Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
  • Table 106 South America Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
  • Table 107 South America Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
  • Table 108 South America Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
  • Table 109 South America Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
  • Table 110 South America Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
  • Table 111 South America Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 112 South America Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
  • Table 113 South America Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
  • Table 114 South America Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
  • Table 115 South America Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 116 Middle East & Africa Cancer Vaccines Market Outlook, By Country (2020-2028) ($MN)
  • Table 117 Middle East & Africa Cancer Vaccines Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 118 Middle East & Africa Cancer Vaccines Market Outlook, By Preventive Cancer Vaccines (2020-2028) ($MN)
  • Table 119 Middle East & Africa Cancer Vaccines Market Outlook, By Therapeutic Cancer Vaccines (2020-2028) ($MN)
  • Table 120 Middle East & Africa Cancer Vaccines Market Outlook, By Technology (2020-2028) ($MN)
  • Table 121 Middle East & Africa Cancer Vaccines Market Outlook, By Dendritic Cells (DC) Cancer Vaccines (2020-2028) ($MN)
  • Table 122 Middle East & Africa Cancer Vaccines Market Outlook, By Recombinant Cancer Vaccines (2020-2028) ($MN)
  • Table 123 Middle East & Africa Cancer Vaccines Market Outlook, By Whole-cell Cancer Vaccines (2020-2028) ($MN)
  • Table 124 Middle East & Africa Cancer Vaccines Market Outlook, By Antigen/Adjuvant Cancer Vaccines (2020-2028) ($MN)
  • Table 125 Middle East & Africa Cancer Vaccines Market Outlook, By Viral Vector & DNA Cancer Vaccines (2020-2028) ($MN)
  • Table 126 Middle East & Africa Cancer Vaccines Market Outlook, By Subunit Vaccines (2020-2028) ($MN)
  • Table 127 Middle East & Africa Cancer Vaccines Market Outlook, By Conjugate Vaccines (2020-2028) ($MN)
  • Table 128 Middle East & Africa Cancer Vaccines Market Outlook, By Inactivated Vaccines (2020-2028) ($MN)
  • Table 129 Middle East & Africa Cancer Vaccines Market Outlook, By Live Attenuated Vaccines (2020-2028) ($MN)
  • Table 130 Middle East & Africa Cancer Vaccines Market Outlook, By Other Technologies (2020-2028) ($MN)
  • Table 131 Middle East & Africa Cancer Vaccines Market Outlook, By Application (2020-2028) ($MN)
  • Table 132 Middle East & Africa Cancer Vaccines Market Outlook, By Prostate Cancer (2020-2028) ($MN)
  • Table 133 Middle East & Africa Cancer Vaccines Market Outlook, By Cervical Cancer (2020-2028) ($MN)
  • Table 134 Middle East & Africa Cancer Vaccines Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 135 Middle East & Africa Cancer Vaccines Market Outlook, By End User (2020-2028) ($MN)
  • Table 136 Middle East & Africa Cancer Vaccines Market Outlook, By Pediatrics (2020-2028) ($MN)
  • Table 137 Middle East & Africa Cancer Vaccines Market Outlook, By Adults (2020-2028) ($MN)
  • Table 138 Middle East & Africa Cancer Vaccines Market Outlook, By Other End Users (2020-2028) ($MN)